A

Apellis Pharmaceuticals

783 employees

Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Nephrology
Hematology
Amyotrophic Lateral Sclerosis (ALS)
Gene Therapy
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pharmaceutical
Complement System
Neurology
Health Care
Geographic Atrophy (GA)
Therapeutics
C3 Glomerulopathy (C3G)
Ophthalmology
Targeted C3 Therapies
Cold Agglutinin Disease (CAD)

Date founded

2008

Funding rounds raised

Total raised

$60M

from 21 investors over 21 rounds

A

Apellis Pharmaceuticals raised undisclosed on January 1, 2020

Investors: Solasta Ventures

A

Apellis Pharmaceuticals raised $60M on August 10, 2017

Investors: Sectoral Asset Management, venBio Partners, Morningside Venture Capital 晨兴资本, Epidarex Capital, Sofinnova Ventures, Russia technology fund, F-Prime Capital Partners and Vivo Capital

A

Apellis Pharmaceuticals raised $47M on February 12, 2016

Investors: AJU IB INVESTMENT, Hillhouse Capital Management, venBio Partners and Epidarex Capital

A

Apellis Pharmaceuticals raised $33M on December 2, 2014

Investors: AJU IB INVESTMENT and Morningside Private Investors

A

Apellis Pharmaceuticals raised $6M on August 2, 2013

Investors: Keyhorse Capital

A

Apellis Pharmaceuticals raised $20K on April 5, 2013

Investors: XLerateHealth

A

Apellis Pharmaceuticals raised undisclosed on July 18, 2012

Investors: Keyhorse Capital

A

Apellis Pharmaceuticals raised $3M on June 20, 2011

Investors: HealthCare Ventures LLC, Keyhorse Capital and Pegasus Capital Advisors

A

Apellis Pharmaceuticals raised $1.7M on May 21, 2010

Investors: Keyhorse Capital

FAQ